Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1969 1
1986 1
1987 1
1996 3
1998 1
2013 1
2014 1
2015 1
2019 1
2020 2
2021 2
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, Sikic D, Wullich B, Bolenz C, Roghmann F, Hölzel M, Ritter M, Strieth S, Hartmann A, Erben P, Wirtz RM, Landsberg J, Dietrich D, Eckstein M. Klümper N, et al. Among authors: jarczyk j. Oncoimmunology. 2023 Oct 19;12(1):2267744. doi: 10.1080/2162402X.2023.2267744. eCollection 2023. Oncoimmunology. 2023. PMID: 37868689 Free PMC article.
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Klümper N, et al. Among authors: jarczyk j. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. Eur J Cancer. 2022. PMID: 35366569 Free article.
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Haas M, Zengerling F, Bolenz C, Burger M, Hartmann A, Kriegmair MC; BRIDGE Consortium e.V.. Breyer J, et al. Among authors: jarczyk j. Sci Rep. 2023 Sep 18;13(1):15437. doi: 10.1038/s41598-023-42088-z. Sci Rep. 2023. PMID: 37723173 Free PMC article.
Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy.
Neuberger M, Weiß C, Goly N, Skladny J, Nitschke K, Wessels F, Kowalewski KF, Waldbillig F, Hartung F, Nientiedt M, Egen L, Herrmann J, Jarczyk J, Walach MT, Kriegmair MC, Westhoff N, Worst TS, Nuhn P. Neuberger M, et al. Among authors: jarczyk j. Discov Oncol. 2022 Dec 15;13(1):140. doi: 10.1007/s12672-022-00603-0. Discov Oncol. 2022. PMID: 36522513 Free PMC article.
Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
Neuberger M, Skladny J, Goly N, Wessels F, WEIß C, Egen L, Erben P, GROß-Weege M, Grüne B, Hartung F, Herrmann J, Honeck P, Jarczyk J, Kowalewski KF, Mühlbauer J, Nitschke K, Nientiedt M, Walach MT, Waldbillig F, Westhoff N, VON Hardenberg J, Kriegmair M, Worst TS, Nuhn P. Neuberger M, et al. Among authors: jarczyk j. Anticancer Res. 2022 Apr;42(4):1911-1918. doi: 10.21873/anticanres.15668. Anticancer Res. 2022. PMID: 35347010
24 results